



RECEIPT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: CLW 2 0147

RECEIVED
APR 10 2003
TECH CENTER 1600/2900

In re application of: Seema Garde, et al.

Serial No. 09/977, 406
Filed: October 15, 2001

Group No.: 1615
Examiner: Unknown

For: PHARMACEUTICAL PREPARATIONS AND METHODS FOR INHIBITING TUMORS

Assistant Commissioner for Patents
Washington D.C. 20231

Office of Initial Patent Examination's
Customer Service Center

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error in that the following data is incorrect:

Foreign Applications


in that the filing receipt should read as follows:

CANADA 2,321,256 10/16/2000
CANADA 2,355,334 08/20/2001

3. Please charge any fees that may be due to Deposit Account No. 06-0308.

Respectfully submitted:

FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP



Timothy E. Nauman, Reg. No. 32,283
1100 Superior Avenue, 7th Floor
Cleveland, Ohio 44114-2518

Tel. No. (216) 861-5582

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.


Mary M. Schriner

Date

March 28, 2003



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/977,406	10/15/2001	1615	6240	CLW 2 0147	30	183	32

Timothy E. Nauman, Esq.
FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP
1100 Superior Avenue, 7th Floor
Cleveland, OH 44114-2516

RECEIVED

MAY 06 2002

FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP

CONFIRMATION NO. 4176

UPDATED FILING RECEIPT



OC00000007975648

Date Mailed: 04/29/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Seema Garde, Montreal, CANADA;
Chandra Panchal, London, CANADA;
Madhulika Baijal-Gupta, London, CANADA;
Jennifer Fraser, London, CANADA;
Salam Kadhim, Kirkland, CANADA;

Assignment For Published Patent Application

PROCYON BIOPHARMA INC.;

Domestic Priority data as claimed by applicant

Foreign Applications

CANADA 2,321,256 10/06/2000
CANADA 2,355,224 08/20/2001

If Required, Foreign Filing License Granted 11/16/2001

Projected Publication Date: 08/08/2002

Non-Publication Request: No

Early Publication Request: No

"DOCKETED"

Title

Pharmaceutical preparations and methods for inhibiting tumors

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



Commissioner for Patents
Washington, DC 20231
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 4176

SERIAL NUMBER 09/977,406	FILING DATE 10/15/2001 RULE	CLASS 514	GROUP ART UNIT 1642	ATTORNEY DOCKET NO. CLW 2 0147
APPLICANTS Seema Garde, Montreal, CANADA; Chandra Panchal, London, CANADA; Madhulika Bajjal-Gupta, London, CANADA; Jennifer Fraser, London, CANADA; Salam Kadhim, Kirkland, CANADA;				
** CONTINUING DATA *****				
** FOREIGN APPLICATIONS ***** CANADA 2,321,256 10/16/2000 CANADA 2,355,334 08/20/2001				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 11/16/2001				
Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Allowance Verified and Acknowledged _____ Examiner's Signature Initials		STATE OR COUNTRY CANADA	SHEETS DRAWING 30	TOTAL CLAIMS 183
INDEPENDENT CLAIMS 32				
ADDRESS Timothy E. Nauman, Esq. FAY, SHARPE, FAGAN, MINNICH & McKEE, LLP 1100 Superior Avenue, 7th Floor Cleveland ,OH 44114-2516				
TITLE Pharmaceutical preparations and methods for inhibiting tumors				
FILING FEE RECEIVED 6240	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	